Abstract Number: Esoc2026a1513 Clinical and Prognostic Significance of Lipoproteins and Their Receptors in Acute Cerebrovascular Diseases

Background and aims Atherosclerosis-related dyslipidemia is a major contributor to acute ischemic stroke pathogenesis. Beyond traditional lipid parameters, lipoprotein(a) [Lp(a)], low-density lipoprotein receptors (LDLR), lectin-like oxidized LDL receptor-1 (LOX-1), and lipoprotein-associated phospholipase A2 (Lp-PLA2) have emerged as key biomarkers reflecting atherogenesis, inflammation, thrombosis, and endothelial dysfunction. This study aimed to investigate the association between these lipid-related biomarkers and the severity of neurological deficits in patients with acute cerebrovascular events. Methods This study included 165 patients admitted with acute cerebrovascular events. Patients were stratified according to neurological deficit severity.Serum levels of Lp(a), Lp-PLA2, LDLR, LOX-1, endothelin and thrombomodulin were measured using enzyme-linked immunosorbent assays.Associations between biomarker levels and clinical severity were analyzed using appropriate statistical methods to assess their prognostic relevance. Results Progression of neurological deficits was associated with a significant 2.3-fold increase in Lp(a) levels and a 2.2-fold decrease in LDLR levels (p<0.01). Patients with severe neurological impairment demonstrated markedly elevated LOX-1 and Lp-PLA2 concentrations, reflecting enhanced inflammatory activity and atherosclerotic plaque instability.Endothelin levels were significantly increased in severe cases, indicating pronounced endothelial dysfunction.Strong correlations were observed between biomarker alterations and neurological deficit severity. Conclusions Dysregulation of lipoproteins and their receptors plays a pivotal role in the pathophysiology of acute cerebrovascular events.Elevated Lp(a),LOX-1 and Lp-PLA2 levels combined with reduced LDLR expression are closely associated with worsening neurological outcomes.These biomarkers may serve as valuable tools for risk stratification, prognostic assessment, and the development of personalized preventive and therapeutic strategies in patients with atherosclerosis-related stroke. Conflict of interest Nothing to disclose